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Abstract
Introduction and hypothesis Faecal incontinence (FI) is prevalent in postmenopausal women. Oestrogen receptors have been
identified in the anal sphincter and have been implicated in the pathogenesis and potential treatment. We sought to evaluate the
literature regarding the impact of local and systemic oestrogen therapy on FI in postmenopausal women.
Methods A systematic review of all studies in postmenopausal women was performed to establish how oestrogen therapy affects
FI. Eight articles were deemed eligible for inclusion following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. Their quality was assessed using the Cochrane risk-of-bias tool (RoB-2) and Newcastle–Ottawa
quality assessment scale.
Results One randomised controlled trial (RCT), two cohort studies, one observational and four cross-sectional studies were
identified. The RCT showed an improvement in FI with anal oestrogen (p = 0.002), but this improvement was also observed in
the placebo arm (p = 0.013) and no difference was seen between these groups. A prospective observational study demonstrated
significant improvement with an oestrogen patch (p = 0.004), but had no control group. Conversely, a large prospective cohort
study demonstrated an increased hazard ratio of FI with current (1.32; 95%CI, 1.20–1.45) and previous oestrogen use (1.26; 95%
CI, 1.18–1.34) compared with non-users.
Conclusion All studies had a high risk of bias and had conflicting views on the effects of oestrogen on FI in postmenopausal
women. This review has identified the need for further research in this area by highlighting the paucity of good research for
evidence-based practice. We believe that a further RCT of local oestrogen is mandated to draw a valid conclusion.
Keywords Oestrogen therapy . Faecal incontinence . Postmenopausal . Systematic review . Hormone replacement therapy .
Accidental bowel leakage
Abbreviations
AI Anal incontinence
FI Faecal incontinence
HRT Hormone replacement therapy
MHT Menopausal hormone therapy
OASI Obstetric anal sphincter injury
PICO Population, intervention, comparator and outcome
QoL Quality of life
RCT Randomised controlled trial
RR Relative risk
Introduction
Faecal incontinence (FI) in adults is a debilitating symptom
that can severely impact quality of life (QoL) and represents a
significant socioeconomic burden on the population [1]. It is
likely to be underreported by patients owing to the social
stigma associated with it. Variable definitions and the hetero-
geneous study populations make it difficult to establish the
true incidence. A systematic review by Ng et al., which in-
cluded 38 studies, found the prevalence to range from 2 to
21% for community-based adult females [2].
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The pathogenesis of FI in postmenopausal women is likely
to be multifactorial [3], but risk factors include injury of the
obstetric anal sphincter (OASI) or the pudendal nerve during
childbirth, increasing age [2] and pelvic floor changes second-
ary to menopause [4]. Oestrogen may be implicated and sev-
eral studies have assessed the expression of sex hormone re-
ceptors in the bowel continence mechanism. Haadem et al.,
Oettling et al. and Parés et al. found oestrogen receptors in
anal sphincter samples [5–7]. But in contrast, Rizk et al. did
not identify oestrogen receptors in the rectal mucosa for either
premenopausal or postmenopausal women [8]. Knudsen et al.
found that female rats who had undergone a bilateral oopho-
rectomy had a reduction in cross-sectional area of striated
muscle of the anal sphincters compared with controls [9],
suggesting a hormonal influence. It is known that lack of
oestrogen after menopause contributes to the genitourinary
symptoms of menopause, such as vaginal atrophy, urinary
incontinence, recurrent urinary tract infections and
dyspareunia and these have successfully been treated with
local oestrogen therapy [10–13]. There is conflicting opinion
as to whether oestrogen contributes to or protects from FI.
The objective of this review was to synthesise all the avail-
able evidence on the relationship between local and systemic
oestrogen therapy and faecal incontinence in postmenopausal
women.
Materials and methods
We performed a systematic review of all studies in female
humans without any language restrictions.
Eligibility criteria
The population of interest was postmenopausal women, the
intervention was the use of oestrogen therapy via any route,
the comparator was no oestrogen use, placebo or other therapy
and the outcome was faecal incontinence. All studies dealing
with the above-mentioned population, intervention, compara-
tor and outcome (PICO) of interest were evaluated.
Search strategy and selection of studies
A literature search of the bibliographic databases including
Ovid, Medline , Cochrane library, EMBASE, LILACS,
Global Index Medicus and Cumulative Index to Nursing and
Allied Health Literature (CINAHL) was conducted by a pro-
fessional librarian. The search strategy was based on a number
of relevant medical subheadings (MeSH), words and word
variants. The following key words were used: “menopause”
or “postmenopause” AND “oestrogen replacement therapy”
or “HRT” or “oestrogen” or “hormone” and “replacement”
and “therapy” or “oestrogen only” or “combined” and
“oestrogen” and “progesterone” AND “faecal incontinence”
or “faeces” or “bowel” or “anal” and “incontinence”.
The reference lists of the identified articles were searched
and a grey literature search was performed to identify any
other relevant articles or presentations (Annual Meetings
screened for potential articles of interest: International
Urogynecological Association [IUGA] 2014–2018 and
International Continence Society [ICS] 2014–2017 [2018
not available]). Two reviewers then independently screened
the titles and abstracts of all the articles and any disagreements
were resolved through discussion or if required, by an inde-
pendent third reviewer (PL). Full texts of the potentially eli-
gible articles were then reviewed and assessed. One paper,
only available in Portuguese, was translated into English for
assessment.
The included studies were assessed for risk of bias using
the Revised Cochrane risk-of-bias tool (RoB-2) [14] and the
Newcastle–Ottawa quality assessment scale [15] where appro-
priate. The data were extracted independently by the two re-
viewers and entered onto a Microsoft Word table.
Results
A total of 148 articles were identified through the literature
search. Twenty-nine full-text articles were retrieved and eight
studies published between 1997 and 2017 were included in
the final analysis. The selection of the articles has been report-
ed in the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) diagram (Fig. 1). The charac-
teristics of the studies included are summarised in Table 1.
There is 1 randomised controlled trial, 2 cohort studies, 1
observational and 4 cross-sectional studies. A meta-analysis
could not be performed because of the heterogeneity of defi-
nition of the condition, intervention and the outcome, as well
as the study designs.
Donnelly et al. [16] performed a prospective observational
study of 20 postmenopausal women in 1997 with established
FI and a low serum oestradiol (<50 pg/ml). Four women who
had previously had a hysterectomy received an oestrogen
patch for 6 months and 16 women with an intact uterus re-
ceived the combination of an oestrogen patch and oral proges-
togen (50 μg oestradiol per 24 h and norethisterone acetate
1 mg daily for 12 days per cycle (Estrapak; Ciba Geigy, Basel,
Switzerland). Patients were assessed using a bowel function
questionnaire (no name given), a continence grading score
(adapted from Pescatori et al. [23]) and a visual analogue score
(VAS; no reference given) for the impact of incontinence on
daily and social activities. Anorectal physiology, which
consisted of anal manometry, anal endosonography, measure-
ment of rectal sensation, anal electrosensitivity and pudendal
nerve terminal motor latency was also tested. After 6 months
of the HRT, 5 out of 20 patients (25%) reported being
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asymptomatic and a further 13 out of 20 (65%) reported some
improvement. The bowel function questionnaire revealed a
significant reduction in the number of women suffering from
flatal incontinence (15 women to 5 women, p = 0.004), faecal
staining of the underwear (10 to 2, p = 0.02) and defaecation
urgency (13 to 6, p = 0.05), whereas a non-significant de-
crease in incontinence related to liquid stool (12 to 6), solid
stool (6 to 3) and difficulty with defaecation (5 to 2) was
demonstrated. No change was reported in the consistency of
stool, requirement of digital manipulation and evacuation his-
tory. The intervention led to a significant improvement in the
median scores for VAS for social activity (median score: 6 to
2, p = 0.001), daily activity (6 to 2, p = 0.001) and the conti-
nence score (15 to 8, p = 0.001). There were significant objec-
tive improvements in mean resting anal canal pressure (33 to
40 mmHg, p = 0.001) and mean squeeze pressure (39 to
43 mmHg, p = 0.03) on anal manometry [16]. A significant
increase in the maximum tolerated rectal volume is reported
but not reflected in the numbers published in the paper
(187 ml to 170 ml). No difference was seen in the anal canal
electrosensitivity (upper 5.3 to 5.2, p = 0.9; lower 4.4 to
4.1 mA; p = 0.3) or pudendal nerve terminal motor latency
(PNTML) (right 2.45 to 2.5 ms, p = 0.5; left 2.46 to 2.44,
p = 0.8). Thirty percent of women included in the study were
found to have a previously unreported anal sphincter defect,
but there were no differences in outcomes between these
subgroups.
Pinedo et al. [17] performed a double-blind randomised
trial to evaluate the effectiveness of topical oestrogen com-
pared with placebo applied to the mucosa of the anal canal.
Thirty-six postmenopausal women without hormonal substi-
tution, with aWexner’s FI score [24] of >5 and < 50% damage
of the external sphincter were given topical estriol (Ovestin) or
placebo to be applied three times a day for 6 weeks to the
mucosa of the anal canal. AWexner score and a quality of life
score (validated and accepted for the spanish language) [25,
26], which included style of life, conduct, depression and em-
barrassment were performed at the beginning and end of the
study. A difference of 50% was considered successful as per
previous research [27, 28] and this was used to calculate the
requirement for 17 patients in each branch. Both branches had
similar patient characteristics. Both groups saw a statistically
significant improvement in Wexner scores (oestrogen 12 to 7:
p = 0.002; placebo 12 to 9: p = 0.013), but there was no
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difference between the two groups (p = 0.521). Both groups
saw minimal non-significant improvements in quality of life
scores following the protocol. Five patients in the estriol group
experienced pruritus ani, which did not require treatment. No
other side effects or complications were reported.
Staller et al. [4] reported from The Nurses’ Health Study,
which was a prospective cohort of 121,701 US female nurses
initiated in 1976, where biennial self-administered question-
naires were completed since its conception. In 2008, questions
about FI were included in the questionnaire, allowing its as-
sociation with menopausal hormone therapy (MHT) in post-
menopausal women to be studied. They stated that they asked
about oral MHT. After exclusions (23,393 died, 13,587 were
lost to follow-up, 15,830 had no FI information, 5,737 had no
MHT information, 7,325 had baseline FI), Staller et al. report-
ed on a cohort of 55,828 nurses. Women returned question-
naires in 2008, 2010 and 2012 about lifestyle factors, medical
diagnosis, FI and exposure to MHT. Lifestyle factors and
medical diagnoses considered were BMI, smoking, physical
activity, parity, history of cholecystectomy, diabetes, hyper-
tension and presence of neurological disease. The definition
of FI was at least one solid or liquid faecal incontinence epi-
sode monthly. The number of months used, current use and
type of MHT were recorded. Because of the assumed associ-
ation with hormones, the analysis includedmeasures that were
surrogates for endogenous and exogenous oestrogen expo-
sure, including parity, age at menopause, oral contraceptive
use, ovulatory duration and type of menopause (surgical, ra-
diation, natural). Of the 55,828 postmenopausal women eligi-
ble for the analysis, 6,834 developed FI (48% liquid, 40%
solid and 12% solid and liquid). The multivariate-adjusted
hazard ratios for incident FI were 1.32 (95% CI 1.20–1.45)
for current users and 1.26 (95%CI 1.18–1.34) for past users of
MHT compared with women who had never used MHT. The
type of MHT altered the risk of FI in a subgroup analyses of
current users: the multivariate hazard ratio was 1.37 (95% CI
1.10–1.71) for current users of combined formulations when
compared with current users of oestrogen-only preparations.
Women who were current users of MHT were younger at
menopause, less likely to be obese or have diabetes and more
likely to have had a surgically/radiation-induced menopause
and to have used oral contraception. A longer duration of
MHT increased the risk of FI with a multivariate adjusted risk
of 1.22 (95%CI 1.13–1.31) for 1–5 years of use, 1.24 (95%CI
1.15–1.35) for 6–10 years of use, and 1.32 (95% CI 1.23–
1.41) for >10 years’ use (plinear trend < 0.0001). The risk ap-
pears to return to baseline after >2 years of discontinuation of
MHT [4].
Lawrence et al. [19] performed a cross-sectional study of
patients enrolled in a health care plan in California (Kaiser
Permanente), using the Epidemiology of Prolapse and
Incontinence Questionnaire (EPIQ) [29] to compare the pres-
ence of anal incontinence (AI) in postmenopausal women
with different oral hormone therapy usage versus premeno-
pausal women. Out of 4,103 women available for analysis,
914 were postmenopausal with no hormones (22.3%), 1,210
were postmenopausal women who had used hormones in the
past (29.5%) and 527 were on hormone therapy (12.8%) at the
time of the study. There were a total of 877 cases of AI—
defined as leakage of gas as well as solid and liquid stool—
and they found that hormone therapy in postmenopausal
women increased the risk of AI. 15.6% of premenopausal
women had AI compared with 22.1% who were menopausal
with no hormone therapy (adjusted OR 1.22 [0.86–1.72]),
32.1% who had had hormone therapy in the past (1.91
[1.35–2.71]) and 30.8% who were currently on hormone ther-
apy (1.65 [1.13–2.40]).
Goode et al. [20] performed a similar cross-sectional sur-
vey on Medicare beneficiaries (Alabama), asking “In the past
year, have you had any loss of control of your bowels, even a
small amount, that stained the underwear?” A univariate anal-
ysis showed that significantly more (p = 0.03) women with FI
were using oestrogen replacement therapy (55.2%) than those
who did not have FI (40.2%), but in a multivariate analysis, it
was found to be non-significant (p value not recorded).
Soerensen et al. [18] performed a longitudinal prospective
cohort study in women who had undergone primary OASI
repair identified from the Danish National Registry compared
with controls on either side of the birth register. A question-
naire was sent out in 1989, 1992 and 2007. FI was defined as
uncontrolled passage of flatus, liquid or solid stool and was
graded by severity using the Wexner continence grading scale
[24], the St. Mark incontinence score [30] and a QoL ques-
t i onna i r e (TH Rockwood Ques t ionna i r e [26 ] ) .
Postmenopausal oral hormone therapy was included to look
at long-term risk in these patients and showed a trend towards
some protective effect against FI (relative risk [RR] 0.66, 95%
CI 0.41–1.06, p 0.06). The adjusted RR followingmultivariate
analysis was not significant at 0.71 (95% CI 0.44–1.31).
De Oliveira et al. [22] performed a cross-sectional study of
100 postmenopausal women in 2003–2004 attending the
Menopause Outpatient Clinic of the State University of
Campinas (Campinas, Spain). The definition of FI was the
presence of one or more episodes of loss of solid or liquid
stool in the last 30 days and the St. Mark score was used to
assess severity. No association between hormone therapy and
FI was found.
Bohle et al. [21] performed a cross-sectional observational
multicentre study where 322 patients, selected at random,
were questioned while attending a primary care setting
(Barcelona, Spain). FI was defined as the involuntary loss of
flatus or liquid/solid stool occurring during the last 4 weeks.
The severity of FI was assessed using the St. Mark (Vaizey)
Incontinence score (0–24) [30]. Data were available for 229
postmenopausal women regarding hormone therapy and FI.
Of these, 28 out of 192 (14.4%) women without FI were
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taking hormone therapy and 5 out of 37 (13.5%) women with
FI were taking hormone therapy. No statistical difference was
found in hormone therapy usage with regard to FI (p = 0.884).
Eight studies were included in this systematic review to
assess the effect of exogenous oestrogen on FI in postmeno-
pausal women. The studies indicated variable results, from
some benefit to worsening of FI. All the studies included
had a risk of bias and were not found to be of high quality
on the Cochrane risk-of-bias tool and Newcastle–Ottawa scale
(Tables 2, 3).
The first paper, published in 1997, was a small observa-
tional study with neither a comparison group nor blinding and
therefore had a high risk of bias [16]. Objective and subjective
approaches to patient outcomes were assessed and the testing
was very thorough. The interventionwas not uniform, as some
patients received combined oestrogen and progesterone re-
placement, whereas some had oestrogen alone but no com-
ments were made as to whether this altered the outcome. The
authors reported that all women completed the study, but did
not specifically comment on compliance to medications. No
information was given on the two patients who did not im-
prove. The RCT performed [17] demonstrated “some con-
cerns” when assessed using the Cochrane risk-of-bias tool
[14]. It was double-blinded and had a robust randomisation
method; however, it did not follow the “intention-to-treat”
analysis (Table 2) and there is no record of compliance to
medication. The nurses cohort study [4] has large numbers
and is prospective; however, the population is selective
(nurses only) and there is a risk of bias owing to self-
completion of the questionnaires. It controlled for con-
founders associated with FI and other exposure to oestrogen.
Initially, it was stated that the hormone therapy recorded in
this study consisted of oral preparations only, although the
authors later stated that they could not be sure that there were
not some that were wrongly classified and that some of the
participants were using topical preparations. The study by
Soerensen et al. was not designed to look specifically at hor-
mone therapy and postmenopausal FI; thus, although useful
information can be taken from it, the study design cannot be
assessed on this basis [18]. The remaining studies were cross-
sectional surveys with inherent bias and some were not de-
signed to explore faecal incontinence as the main outcome
[19–21].
Discussion
We believe that this is currently the only review collating all
the evidence available related to the impact of oestrogen on FI
for postmenopausal women. The role of oestrogen therapy
(vaginal, anal, systemic) in the treatment of FI in postmeno-
pausal remains unclear because of limited high-quality data,
but there is biological plausibility.
Table 3 Newcastle–Ottawa
Quality Assessment Scale for
Cohort Studies
Study reference Soerensen et al.
[18]
Staller et al. [4]
Study design Cohort Prospective
cohort
Representativeness of the exposed cohort 0 0
Selection of the non-exposed cohort 1 1
Ascertainment of exposure 0 0
Demonstration that the outcome of interest was not present at the start of
the study
0 1
Comparability on the basis of the design or analysis 0 2
Assessment of outcome 0 0
Adequate follow-up period 1 0
Adequacy of follow-up 1 0
Overall 3 out of 9 4 out of 9
Table 2 Revised Cochrane risk-of-bias tool for randomised trials (RoB 2)
RCT Bias from the
randomisation
process
Effect of
assignment to
intervention
Effect of adhering
to intervention
Bias due to
missing outcome
data
Bias in
measurement of the
outcome
Bias in selection of
reported result
Overall
risk of bias
Pinedo
et al.
[17]
Low Some concerns Low Low Low Low Some
concerns
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The mechanism suggested for the improvement reported in
the first study by Donnelly et al. [16] was increased resting
pressure of the internal sphincter due to the improved func-
tionality related to oestrogen causing alteration of collagen
and elastic content of the pelvic floor. The subjective benefi-
cial effects observed may have been related to an actual im-
provement in symptoms, but could also have been due to
improved general wellbeing owing to increased circulating
oestrogen from systemic administration and it is difficult to
separate these effects [16]. The next study [17] found that
topical anal oestrogens improved symptoms of FI; however,
the placebo group also improved, highlighting a complex
pathophysiology for FI with potential psychological overlay
altering the patients’ perception of the condition and therefore
altering the subjective outcomes. In contrast to these first two
studies, in 2017, the large prospective cohort study [4] gave a
hypothesis of oestrogen-mediated loss of connective tissue
from the internal sphincter and levator ani to explain the in-
creased FI with current and previous oestrogen use. The in-
creased effect seen with combination therapy is attributed to
progestin, causing both increased oestrogen receptors on the
anorectum and a direct effect on oestrogen at a nuclear level. It
is difficult to establish, in this particular study, whether exog-
enous oestrogen increases the risk of FI or whether women
taking exogenous oestrogen are those who are affected most
by both menopausal symptoms and FI and may have lower
natural oestrogen levels. Although all the studies discussed
add value to this systematic review, Staller et al.’s finding of
increased risk of FI with oestrogen use is potentially a key
finding that should be investigated promptly [4]. Faecal incon-
tinence could be an under-reported but considerable side ef-
fect of the widespread use of hormone therapy in postmeno-
pausal women.
With the ageing population worldwide, FI is a growing
problem that needs to be addressed [2]. There is no definitive
answer that we can give as to whether oestrogen therapy is
helpful or harmful with regard to FI in postmenopausal wom-
en, but this review has certainly indicated the scope for further
research in this field. Based on biological plausibility and lack
of current studies establishing the role of oestrogen therapy on
FI, high-quality studies examining the impact of oestrogen on
FI are warranted. Standard definitions would aid our field in
interpreting the impact of interventions on FI.
In conclusion, this review has highlighted the paucity
of good-quality evidence in this area. We would suggest
that a further randomised controlled trial (RCT) might
be required to draw a valid conclusion. However, the
challenges to this would be how to define faecal incon-
tinence, in particular, the frequency of incontinence that
is appropriate, and how much of an improvement is
classed as a “success”. Using any systemic hormone
therapy is associated with risks and an RCT to assess
the effect of systemic oestrogen on faecal incontinence
may be technically and ethically difficult to design; vag-
inal oestrogen might be more appropriate.
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